Aflibercept
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Aflibercept: VEGF-A/VEGF-B/PlGF trap → esotropia
One-Sentence Summary
Aflibercept is a VEGF trap protein marketed in Canada under several brand names, mainly for eye conditions. The TxGNN model predicts it may be relevant to esotropia, but no clinical trials and no publications in the data compiled for this report support this direction, so it rests on the model prediction alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | esotropia |
| TxGNN Prediction Score | 0.9938 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 10 of 10) |
| Number of DINs | 10 (marketed: 10) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Aflibercept acts as a decoy receptor (“trap”) that binds VEGF-A, VEGF-B and placental growth factor (PlGF). Detailed mechanism-of-action data were not available in the data compiled for this report, so this description relies on the drug’s known class.
Esotropia is a form of strabismus (inward turning of the eye) driven mainly by neuromuscular and sensorimotor factors. No clear mechanistic route from VEGF/PlGF blockade to esotropia is evident. The high score (0.9938) is a model output only; no trial or publication in the compiled data backs it. The prediction should be treated as a hypothesis, not as a supported repurposing opportunity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02415992 | EYLEA | Not recorded | Not recorded |
| 02505355 | EYLEA | Not recorded | Not recorded |
| 02545004 | EYLEA HD | Not recorded | Not recorded |
| 02554798 | EYLEA HD | Not recorded | Not recorded |
| 02558238 | YESAFILI | Not recorded | Not recorded |
Ten licences are currently valid in total (also covering AFLIVU, PAVBLU, ENZEEVU and further YESAFILI products); the table shows five of them.
Safety Considerations
- Drug Interactions: 78 interactions were identified. Major-level examples include deferiprone, samarium (153Sm) lexidronam, adalimumab, baricitinib, certolizumab pegol, cladribine and clozapine. Moderate-level examples include strontium chloride Sr-89, roflumilast, chloramphenicol, zidovudine and azathioprine.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score but no supporting trials or publications, and no plausible mechanistic link to esotropia is evident. Evidence level is L5.
To proceed, the following is needed:
- Mechanistic evidence linking VEGF/PlGF blockade to esotropia, or preclinical data
- Package insert warnings and contraindications from Health Canada
- Detailed mechanism of action data
- Any clinical or observational studies directly addressing esotropia
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.